Oral fluid compliance monitoring of chronic pain patients is an analytical challenge because of the limited specimen volume and the number of drugs that require detection. This study evaluated oral fluid for monitoring pain patients and compared results to urine studies of similar populations. Oral fluid specimens were analyzed from 6441 pain patients from 231 pain clinics in 20 states. Specimens were screened with 14 ELISA assays and nonnegative specimens were confirmed by LC-MS-MS for 40 licit and illicit drugs and metabolites. There was an 83.9% positive screening rate (n = 5401) of which 98.7% (n = 5329) were confirmed at ≥ LOQ concentrations for at least one analyte. The prevalence of confirmed positive drug groups was as follows: opiates > oxycodone > benzodiazepines > methadone ≈ carisoprodol > fentanyl > cannabinoids ≈ tramadol > cocaine > amphetamines ≈ propoxyphene ≈ buprenorphine > barbiturates > methamphetamine. Approximately 11.5% of the study population of pain patients apparently used one or more illicit drugs (cannabis, cocaine, methamphetamine and/or MDMA). Overall, the pattern of licit and illicit drugs and metabolites observed in oral fluid paralleled results reported earlier for urine, indicating that oral fluid is a viable option for use in compliance monitoring programs of chronic pain patients.
Introduction
Chronic pain is a leading cause for physician visits (1) . Pain management specialists have an ever-expanding array of therapeutic drugs to treat chronic pain, but have concerns about compliance, potential toxic side-effects, addiction, diversion of controlled substances, concomitant patient use of illegal drugs or non-prescribed prescription drugs, and professional liability. Ongoing patient assessment is essential to responsible prescribing. Many physicians advocate a patient-centered model of urine drug testing as a means of improving quality of care and providing objective information about what the patient is taking (2) . There is considerable support for the effectiveness of urine tests in pain practices. For example, Katz et al. (3) examined the role of urine toxicology, in addition to behavioral monitoring, in patients receiving opioid therapy for chronic pain. That study found that 21% of patients with no behavioral issues tested positive for an illicit drug or a non-prescribed drug. Others have evaluated urine tests and concluded that compliance monitoring practices that include urine testing were effective in reducing illicit drug use and controlled substance abuse in chronic pain patients (4, 5) .
Oral fluid is an alternate matrix to urine for drug testing and has been the topic of extensive study. A variety of reviews have appeared that describe inherent advantages and disadvantages of oral fluid testing (6) (7) (8) (9) (10) (11) (12) and its application in different fields such as workplace testing (8, 11, 13) , diagnostics (14) , roadside drug testing (7, (15) (16) (17) , and legal issues (18) . The technology for accurate measurement of multiple drugs and metabolites in oral fluid specimens has also advanced considerably over the last decade. Whereas early analytical methods for oral fluid analyses were primarily based on gas chromatography-mass spectrometry (GC-MS) and tandem GC-MS methods (19) (20) (21) , liquid chromatography-tandem MS (LC-MS-MS) has emerged as a preferred technology for analysis (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) .
Recently, physicians have recognized the advantages of oral fluid as an alternate matrix for compliance monitoring; however, to the authors' knowledge, there appears to be no published studies of the use of oral fluid for compliance monitoring of pain patients. This study is part of an ongoing research effort to improve drug testing methods for monitoring pain patients (35) (36) (37) . The lack of toxicological information on drug testing of oral fluid specimens from pain patients led us to assemble a database made up of 6441 screening and confirmation results from 231 pain clinics in 20 states. The database contained qualitative and quantitative information on 40 drug/metabo- lites originating from 14 drug classes. The goals of the study were to characterize the performance of oral fluid screening assays compared to LC-MS-MS, report prevalence patterns of prescribed drugs and metabolites, determine the incidence of amphetamines, cannabis, cocaine, and ecstasy-type drug use in this population, and compare overall oral fluid results to earlier studies of urine testing of pain populations.
Experimental
Standards and reagents Drugs, metabolites, and deuterium-labeled internal standards were purchased from the following sources: Alltech Applied Sciences (State College, PA); Biomol Research Labs (Plymouth Meeting, PA); Cerilliant (Round Rock, TX); Lipomed (Cambridge, MA); Medical Isotopes (Pelham, NH); SigmaAldrich (St. Louis, MO); and USP (Rockville, MD). Tramadol, N-desmethyltramadol, and O-desmethyltramadol were obtained from the RW Johnson Pharmaceutical Research Institute (San Diego, CA). All solvents were of HPLC grade or higher; all reagents were ACS grade and purchased from Spectrum Chemical (Gardena, CA). Oral fluid buffer was purchased from Immunalysis (Pomona, CA).
Patients and specimens
Oral fluid specimens were collected from chronic pain patients over the period of January 1, 2010, through September 10, 2010 , from 231 pain clinics located in 20 states (AL, FL, GA,  IL, KY, LA, MD, MS, NC, NJ, NV, NY, OH, PA, SC, TN, TX, UT, VA, and WV). All patients were enrolled in pain management compliance monitoring programs that included drug testing for licit and illicit drugs. The study was approved by the Essex Institutional Review Board (Lebanon, NJ). Oral fluid specimens were collected per manufacturer's instructions with Quantisal™ (Immunalysis) saliva collection devices. The Quantisal collection device consists of a cellulose pad affixed to a plastic stem that has a volume adequacy indicator. The pad was placed under the tongue of an individual and remained until a defined volume of oral fluid (1 mL) saturated the pad as evidenced by the indicator turning blue. When sufficient volume was collected, the pad was removed and placed in a transport tube containing 3 mL of buffer with preservative. The tube was capped, labeled, and stored at room temperature until shipment to the laboratory for analysis.
The specimens (n = 6441) were analyzed by Aegis Sciences (Nashville, TN). Screening and confirmation data were assembled into a database containing only test results, state of origin, and coded identifiers to protect patient confidentiality.
Oral fluid analyses
Oral fluid specimens were initially screened with 14 enzymelinked immunosorbent assays (ELISA) for a broad range of licit and illicit drugs. The ELISA assays, their cutoff concentrations, and percent cross-reactivity data are listed in Table I .
Confirmation analyses of non-negative samples were performed by validated LC-MS-MS procedures. Drugs and metabolites measured in oral fluid are listed in Table I along with their associated lower limit of quantitation (LOQ). Specimens were prepared for analyses by either liquid-liquid extraction (LLE) or solid-phase extraction (SPE). For the LLE procedure, 500 µL of oral fluid sample from the collection device was fortified with deuterated internal standards and extracted with a 1:4 mixture of hexane/ethyl acetate. The organic phase was separated and evaporated, and the residue was reconstituted with 200 µL of 10 mM ammonium acetate, 0.1% formic acid HPLC water (mobile phase). For SPE analysis, a GV-65 column (Biochemical Diagnostics, Edgewood, NY) was used. Oral fluid specimens were fortified with deuterated internal standards, mixed with 0.25 M phosphate buffer (pH 6), and loaded onto a conditioned SPE column. The column was washed with deionized water, 0.01 M acetic acid, and methanol and then eluted with 1:1 acetone/chloroform. The organic eluate was separated, evaporated, and the extract was reconstituted with 200 µL (50 µL for THC and THCCOOH) of mobile phase. LC-MS-MS analyses were performed with an AB Sciex 4000 Q-trap MS and a Shimadzu LC-20AD HPLC. The mobile phase was 10 mM ammonium acetate, 0.1% formic acid HPLC water, and 0.1% formic acid acetonitrile. The HPLC column was a Restek Pinnacle DB C 18 (3 µm, 100 × 2.1 mm). All analyses were performed with electrospray ionization (positive mode or negative mode). The conditions for analysis were as follows: curtain gas, 30 psi; collision-activated dissociation, 5 psi; heated nebulizer temperature, 650°C; gas 1, 70 psi; and gas 2, 65 psi. To identify the appropriate multiple reaction monitoring (MRM) transitions and analysis conditions for each compound, solutions of standards in methanol/water (50:50, v/v) were infused into the MS, and the declustering potential and collision energies were optimized for each compound. MRM transitions for the 40 analytes and their associated internal standards are listed in Table II . Data acquisition, peak integration, and calculation were performed using a computer workstation running Analyst 1.4.2 software. Low and high control samples (n = 10) of the 40 analytes were prepared in oral fluid buffer (Immunalysis). Analyte concentrations for the low and high control samples were generally targeted at onehalf and twice the calibrator concentrations, respectively. The mean and median intraassay precision (%CV) across the 40 analytes were as follows: low control, 6.5%, 6.7% and high control, 6.3%, 6.6%. The mean and median absolute accuracy (% deviation from target concentration) across the 40 analytes were as follows: low control, 11.1%, 7.6% and high control, 10.5%, 7.8%.
Criteria for identification and measurement of analytes in oral fluid were as follows: the relative retention time (RRT) of each analyte in the sample was required to be within ±0.006 of its respective RRT in the calibrator or the retention time (RT) of each analyte in the sample was required to be within ±3% of its re- * True positives were identified as those specimens that screened non-negative and were confirmed by LC-MS-MS for drug and/or metabolite at concentrations ≥ LOQ. False positives were identified as those specimens that screened non-negative but had concentrations of drug and metabolite < LOQ by LC-MS-MS assay. The % true positives and false positives were calculated by division of their number by the total number that screened positive and multiplication × 100. † The % non-negatives were calculated by division of the number of specimens that screened positive by 6441 and multiplication × 100.
spective RT in the calibrator; ion ratios for the product ions derived from analytes and internal standards in controls and donor specimens had to be within ±20% of the mean range of the corresponding analytes in the calibrator; control sample concentrations had to measure within ± 20% of the in-house determined mean value; and negative controls could not contain analytes above the LOQ. The LOQ for each analyte was determined by serial dilutions of oral fluid samples fortified with known drug concentrations. The lowest concentration that could be accurately measured (±20% of target concentration) and met identification criteria was defined as LOQ. The upper limit of linearity (ULOL) was defined as the maximum concentration that could be accurately measured (±20% of target concentration) and also met all identification criteria. Included in this report are all quantitative data for drugs and metabolites that met identification and quantitation (≥ LOQ) criteria. Analyte concentration in oral fluid was adjusted for the fourfold dilution (1 mL oral fluid added to 3 mL buffer) with the Quantisal collection device in order to represent native oral fluid concentration.
Results and Discussion
Overall positive prevalence rates in screening and confirmation assays The analyses of the 6441 oral fluid specimens submitted to the laboratory over the period from January 1, 2010, through September 10, 2010, followed the traditional mode of forensic analyses comprised of initial immunoassay screening and LC-MS-MS confirmation of non-negative samples. Fourteen ELISA-based screening assays were employed for screening. The threshold concentrations and cross-reactivity data for the screening assays are listed in Table I . A combined total of 10,962 initial non-negative results were obtained for the specimens. There was a mean ± SD (median, range) of 1.7 ± 1.2 (2, 0-8) non-negative screening results per specimen for the 6441 specimens. A total of 1040 specimens tested negative by the 14 ELISA assays; hence, no further testing was performed with these specimens. Thus, 5401 specimens screened non-negative (83.9% positive screening rate) for at least one drug category. The prevalence of single and multiple non-negative screening results per specimen were as follows: single positive, n = 2070; two positives, n = 1791; three positives, n = 1032; four positives, n = 361; five positives, n = 119; six positives, n = 22; seven positives, n = 5; and eight positives, n = 1.
The 5401 specimens that screened non-negative for at least one drug category were analyzed by LC-MS-MS for the potential presence of 40 drugs and/or metabolites. The confirmation analytes and their respective LOQs for each drug category are listed in Table I . For the purposes of this study, an analyte was considered confirmed positive if it tested by LC-MS-MS at ≥ LOQ concentration and met qualitative criteria for identification. A combined total of 17,246 positive results (analytes with concentrations ≥LOQ) were obtained for the 5401 specimens. There was a mean ± SD (median, range) of 3.2 ± 1.8 (3, (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) analytes per specimen for the 5401 specimens. A total of 72 non-negative screened samples tested negative for all analytes by LC-MS-MS assays. Thus, 5329 specimens tested positive (82.7% overall positivity rate; 98.7% positive confirmation rate) for at least one drug analyte. These data are similar to a urine drug testing study of 13,948 chronic pain patients in which 10,922 specimens were confirmed positive for at least one analyte (overall 78.3% positivity rate) (35) . The prevalence of single and multiple analytes per specimen in these specimens were as follows: single analyte, n = 869; 2 analytes, n = 1238; 3 analytes, n = 1274; 4 analytes, n = 811; 5 analytes, n = 539; 6 analytes, n = 284; 7 analytes, n = 181; 8 analytes, n = 76; 9 analytes, n = 34; 10 analytes, n = 8; 11 analytes, n = 9; 12 analytes, n = 3; 13 analytes, n = 2; and 14 analytes, n = 1. The high positive prevalence rates observed in the screening and confirmation assays (> 80% positivity) are not unusual considering the pain management patient population. An earlier study of 13,948 urine specimens collected from pain patients in 2008 confirmed 10922 specimens as positive (78% positivity) for one or more drug analytes by GC-MS (35) . In stark contrast, the positivity rate for urine and oral fluid specimens collected in workplace settings has been reported to be typically in the range of 2-5% (21,38).
Positive prevalence rates for screening and confirmation assays
Positive prevalence rates for the 14 screening assays and confirmation results of the oral fluid specimens are shown in Table III along with confirmation results. As expected, the highest non-negative rates in screening assays were observed for the Opiate (51.8%) and Oxycodone (40.5%) drug classes followed in lower abundance by benzodiazepines (15.7%) and methadone (11.1%). Non-negative screening results for the remaining drug classes ranged from 1 to 9.9%. Similar trends in screening test results across these drug classes were reported in a study of urine specimens obtained from 10922 pain patients (35) .
LC-MS-MS analyses allowed for determination of the true positive and falsepositive rates of the screening assays. A "True Positive" was defined as a specimen that screened positive at or above the threshold concentration and was con- firmed positive by LC-MS-MS at ≥ LOQ for at least one of the confirmation analytes listed in Table I for each drug class. A "False Positive" was defined as a specimen that screened nonnegative at or above the threshold concentration, but was negative by LC-MS-MS at the LOQ for all of the confirmation analytes for the drug class. The Amphetamines and Methamphetamine screening assays displayed the highest false-positive rates, 56.2% and 36.4%, respectively. The remaining screening assays had variable false-positive rates ranging from 1.1% (benzodiazepines) to 28.1% (barbiturates). Two series of screening assays (amphetamines/methamphetamine and opiates/oxycodone) allowed cross-comparisons between similar assays. Specimens that tested non-negative in either or both Amphetamines and Methamphetamine assays were submitted for LC-MS-MS confirmation for all analytes in both classes. Similarly, specimens that tested non-negative in either or both Opiates and Oxycodone assays were submitted for LC-MS-MS confirmation for all analytes in both classes. Tables IV and  V characterized ) confirmed only for oxycodone analytes, and 4 (0.2%) failed to confirm for either drug group. The lack of correspondence between screening assays and confirmation results for these drug groups highlighted the importance of employing both screening assays for the detection of amphetamine and methamphetamine and for detection of opiates and oxycodone. For example, in this study, screening with the Opiates assay without the Oxycodone screen would have resulted in 854 false-negative specimens that would have confirmed positive for opiates and/or oxycodone.
The concentrations of drugs and metabolites in oral fluid determined by LC-MS-MS are listed in Table VI by individual analyte. Comparison of mean and median concentrations of drugs and metabolites in oral fluid to urine concentrations of pain patients indicate that urine concentrations tended to be substantially greater (frequently > 10-fold) compared to oral fluid (35) . However, comparison of the current results for oral fluid from pain patients to an earlier study of oral fluid specimens collected in the United Kingdom from legal/workplace specimens revealed greater similarities in concentration (38) .
Frequency of drug/metabolite combinations in oral fluid
The different combinations of parent drug and/or metabolites in oral fluid are listed in Table VII . It should be noted that some drug categories contain analytes that may be present either because of drug ingestion or metabolism of another related drug. For example, amphetamine is a drug that is available as a prescription medication, but may also be present as a 
result of metabolism of methamphetamine. Even more complex cases arise for the opiates. Morphine is metabolized to hydromorphone (39) and codeine is metabolized to hydrocodone in minor amounts (40) . Hydrocodone is metabolized to dihydrocodeine and to hydromorphone, both of which are available as prescription medications. Hydrocodone is also metabolized to norhydrocodone which serves as a unique biomarker for hydrocodone ingestion. Two recent studies of urine drug testing of pain patients have emphasized the importance of inclusion of unique "normetabolites" of opiates (36) and opioids (37) in compliance monitoring drug profiles as aids in interpretation of results and prevention of false negatives.
In the current study, it was of interest to determine if N-and O-desalkyl-metabolites were excreted in oral fluid in sufficient abundance to be useful as "biomarkers" of parent drug use. The prevalence of N-desalkyl-metabolites of buprenorphine, carisoprodol, fentanyl, hydrocodone, methadone, oxycodone, propoxyphene, and tramadol and O-desalkyl metabolites for hydrocodone, oxycodone, and tramadol are listed in Table VIII . Overall, N-desalkyl-metabolites were present in relatively high abundance (range 30.4-79.8%) for specimens that contained the parent drug and/or various combinations of metabolites. For the two most widely prescribed analgesics, hydrocodone and oxycodone, the prevalence of their normetabolites in oral fluid (68.4%, 79.8%) was remarkably similar to their prevalence in urine (67.7%, 70.5%) (36) . The abundance of normetabolites of fentanyl, methadone, and propoxyphene in oral fluid also appeared similar to those in urine, whereas norbuprenorphine was detected in 48.5% of the oral fluid specimens positive for buprenorphine compared to 86.8% of urine specimens (37) .
A summary of median drug concentrations in oral fluid compared to urine concentrations reported in previous urine studies is shown in Table IX together with comparisons of ra- tios of parent drug to N-desalkyl-and O-desalkylmetabolites. Codeine/morphine ratios were not included in this evaluation because, in most cases, morphine was the prescribed drug and was not a metabolite of codeine. Also, it should be noted in this comparison that hydromorphone and oxymorphone are considered as metabolites of hydrocodone and oxycodone, respectively, but there is likely to be contribution to their presence from independent use of these agents as analgesics. Despite this limitation, the median ratio estimates for parent drug to O-desalkyl-metabolites provided a means of relative comparison between oral fluid and urine. Overall, concentrations of parent drug to N-desalkyl-metabolites were greater in oral fluid than in urine for buprenorphine, fentanyl, hydrocodone, methadone, and oxycodone. Similarly, the relative concentrations of parent drug to O-desalkyl-metabolites were greater in oral fluid than urine for hydrocodone and oxycodone. The higher abundance of parent drug versus metabolites in oral fluid compared to urine is likely due to a combination of factors including greater lipophilicity of the parent drug, greater degree of conjugation of metabolites, and possible differences in plasma-protein binding between parent drug and metabolites (12) .
Other drug/metabolite combinations of interest in this study included amphetamines, cannabis, carisoprodol/meprobamate, cocaine, MDMA, and tramadol. In the amphetamines category, amphetamine was much more abundant than methamphetamine, likely as a result of greater prescribing of amphetamine. For the cannabis category, the only analyte detected was ∆ 9 -tetrahydrocannabinol (THC). No specimens were identified containing 11-nor-9-carboxy-∆ 9 -tetrahydrocannabinol (THCCOOH). Earlier reports of identification of THCCOOH in oral fluid have indicated that THCCOOH concentrations were in the range of 0.02-0.35 ng/mL (41, 42) . Consequently, the 2 ng/mL LOQ employed in the current study limited detection of this metabolite. For the carisoprodol/ meprobamate category, meprobamate was present in 89.4% of the specimens and was identified as the sole analyte in 18.9%. Although both drugs are available for prescribing, carisoprodol is not a federally scheduled drug whereas meprobamate is a Schedule IV drug. Consequently, carisoprodol is likely to be more widely prescribed than meprobamate. For the cocaine category, cocaine in combination with benzoylecgonine was detected most frequently (74.2%), but 14.6% of the specimens positive for this class contained only cocaine and 11.3% contained only benzoylecgonine. Similar prevalence of cocaine in combination (and absence) with benzoylecgonine in oral fluid specimens has been reported (38) . Only two specimens were identified that contained MDA and/or MDMA. The prevalence of the N-and O-desalkyl-metabolites of tramadol were of interest as they are unique metabolites and the presence of either metabolite can be interpreted as evidence of recent use. The Odesalkyl-metabolite was detected more frequently than either the N-desalkyl-metabolite or tramadol, but exhibited the lowest median concentration of the three analytes (Table VI) .
Possible illicit drug use in pain patients
A total of 747 specimens tested positive for one or more of the following drugs: cannabis, cocaine, methamphetamine, MDMA, and MDA. Of these, four patients who tested positive for cannabis reported being prescribed Marinol ® and two patients who tested positive for methamphetamine reported being prescribed "amphetamines", leaving 741 patients (11.5%) of the study population presumably positive for illicit drug use. Various combinations of illicit drugs were as follows: cannabis (n = 343, 5.3%), cocaine (n = 308, 4.8%), cannabis and cocaine (n = 46, 0.7%), methamphetamine (n = 36, 0.6%), cocaine and methamphetamine (n = 3, 0.05%), cannabis and methamphetamine (n = 2, 0.03%), cannabis and cocaine and methamphetamine (n = 1, 0.02%), cocaine and MDMA (n = 1, 0.02%), and MDMA (n = 1, 0.02%). Although the overall percentage of illicit drug use by chronic pain patients in this study (11.5%) was quite similar to results reported for urine drug testing of a similar population (10.9%) (35) , the prevalence of cannabis and cocaine appeared to differ somewhat compared to urine. Oral fluid positives for cannabis (6.2%) and cocaine (5.6%) were almost equal in the current study, whereas in the prevalence of cannabis (8.9%) was higher than cocaine (2.8%) in urine (35) . These differences in prevalence could be due to a variety of factors including differences in the populations, accuracy of their self-report data concerning their prescribed medications, or differences between urine and oral fluid in time course of detection of these substances.
Conclusions
This study presents a comprehensive evaluation of oral fluid toxicology data arising from testing of chronic pain patients in clinical settings and provides comparisons to earlier studies involving urine testing of similar pain patient populations. The results support the conclusion that oral fluid can be used effectively as an alternate biological specimen for assessment of pain patients in compliance monitoring programs. A total of 6441 oral fluid specimens from pain patients in 231 pain clinics located in 20 states in the United States in 2010 were analyzed by immunoassay with LC-MS-MS confirmation for 40 drugs and/or metabolites.
Significant findings were as follows:
The overall oral fluid non-negative screening rate for 14 drug categories was 83.9%, similar to a rate of 78% for urine reported in an earlier study (35) of pain patients. The prevalence of single and multiple non-negative screening results ranged from one to eight drug categories with an average of 1.7 positives per specimen.
The non-negative specimens from the screening assays were analyzed by LC-MS-MS and confirmed at a rate of 98.7%. The number of confirmed analytes per specimen ranged from 1 to 14 analytes. Confirmation rates of individual screening assays were > 95% for 7 of the 14 drug categories. The Amphetamines and Methamphetamine screening assays displayed the lowest confirmation rate.
The overall prevalence of confirmed positive drug groups was as follows: opiates > oxycodone > benzodiazepines > methadone ≈ carisoprodol > fentanyl > cannabinoids ≈ tramadol > cocaine > amphetamines ≈ propoxyphene ≈ buprenor-phine > barbiturates > methamphetamine. An earlier study of urine from pain patients displayed a similar prevalence rate (35) .
N-Desalkyl-metabolites of buprenorphine, carisoprodol, fentanyl, hydrocodone, methadone, oxycodone, propoxyphene, and tramadol were detected in sufficient concentration and abundance in oral fluid (range 30.4-79.8%) to make them useful in interpretation of test results. The presence of these "biomarkers" clearly indicated recent use of the parent drug. For hydrocodone and oxycodone, the prevalence of their normetabolites in oral fluid (68.4%, 79.8%) was very similar to their reported prevalence in urine (67.7%, 70.5%) (36) .
Approximately 11.5% of the study population of pain patients apparently used one or more illicit drugs. This is similar to an earlier study of pain patients in which 10 .9% of urine specimens tested positive for various combinations of cannabis, cocaine, and ecstasy-type drugs (35) . The various combinations of illicit drug use in this study were as follows: cannabis, 5.3%; cocaine, 4.8%; cannabis and cocaine, 0.7%; methamphetamine, 0.6%; cocaine and methamphetamine, 0.05%; cannabis and methamphetamine, 0.03%; cannabis and cocaine and methamphetamine, 0.02%; cocaine and MDMA, 0.02%; and MDMA, 0.02%.
In general, the pattern of licit and illicit drugs identified in oral fluid specimens paralleled results observed in earlier studies involving urine testing of pain patient populations. Although drug and metabolite concentrations in oral fluid were lower than observed in urine, the overall qualitative patterns were quite similar. The advantages of oral fluid tests (e.g., noninvasive, observed collection) in combination with demonstrated similarity of results to urine appear to make oral fluid a viable option for use in compliance monitoring programs of chronic pain patients.
